Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 202

1.

The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T's come into focus.

Passweg JR, Baldomero H, Chabannon C, Basak GW, Corbacioglu S, Duarte R, Dolstra H, Lankester AC, Mohty M, Montoto S, Peffault de Latour R, Snowden JA, Styczynski J, Yakoub-Agha I, Kröger N; European Society for Blood and Marrow Transplantation (EBMT).

Bone Marrow Transplant. 2020 Feb 17. doi: 10.1038/s41409-020-0826-4. [Epub ahead of print]

PMID:
32066864
2.

Burden of illness among patients with severe aplastic anemia who have had insufficient response to immunosuppressive therapy: a multicenter retrospective chart review study.

Peffault de Latour R, Huynh L, Ivanova JI, Totev T, Bilginsoy M, Antin J, Roy A, Duh MS.

Ann Hematol. 2020 Apr;99(4):743-752. doi: 10.1007/s00277-019-03809-5. Epub 2020 Feb 17.

PMID:
32065291
3.

Cord blood transplantation for bone marrow failure syndromes: state of art.

Pagliuca S, Ruggeri A, Peffault de Latour R.

Stem Cell Investig. 2019 Dec 5;6:39. doi: 10.21037/sci.2019.10.04. eCollection 2019. Review.

4.

Thrombocytapheresis and sequential chemotherapy for extreme symptomatic thrombocytosis secondary to myelofibrosis: a case report.

Debureaux PE, Brignier A, Soret-Dulphy J, Réa D, Michonneau D, Peffault de Latour R, Sicre de Fontbrune F, Pagliuca S, Parquet N, Prata HP, Marouf A, Xhaard A, Kiladjian JJ, Socié G, Robin M.

Ann Hematol. 2020 Apr;99(4):897-898. doi: 10.1007/s00277-020-03948-0. Epub 2020 Feb 7. No abstract available.

PMID:
32030449
5.

The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria.

Röth A, Nishimura JI, Nagy Z, Gaàl-Weisinger J, Panse J, Yoon SS, Egyed M, Ichikawa S, Ito Y, Kim JS, Ninomiya H, Schrezenmeier H, Sica S, Usuki K, Sicre de Fontbrune F, Soret J, Sostelly A, Higginson J, Dieckmann A, Gentile B, Anzures-Cabrera J, Shinomiya K, Jordan G, Biedzka-Sarek M, Klughammer B, Jahreis A, Bucher C, Peffault de Latour R.

Blood. 2020 Mar 19;135(12):912-920. doi: 10.1182/blood.2019003399.

6.

Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria.

Brodsky RA, Peffault de Latour R, Rottinghaus ST, Röth A, Risitano AM, Weitz IC, Hillmen P, Maciejewski JP, Szer J, Lee JW, Kulasekararaj AG, Volles L, Damokosh AI, Ortiz S, Shafner L, Liu P, Hill A, Schrezenmeier H.

Haematologica. 2020 Jan 16. pii: haematol.2019.236877. doi: 10.3324/haematol.2019.236877. [Epub ahead of print]

7.

Effectiveness of brentuximab vedotin before and after allogeneic stem-cell transplantation in the management of transformed mycosis fungoides.

André R, Ram-Wolff C, Battistella M, Peffault de Latour R, Petit A, Bouaziz JD, Brice P, Bagot M, de Masson A.

Br J Dermatol. 2019 Dec 19. doi: 10.1111/bjd.18806. [Epub ahead of print] No abstract available.

PMID:
31854457
8.

Haploidentical transplantation and posttransplant cyclophosphamide for treating aplastic anemia patients: a report from the EBMT Severe Aplastic Anemia Working Party.

Prata PH, Eikema DJ, Afansyev B, Bosman P, Smiers F, Diez-Martin JL, Arrais-Rodrigues C, Koc Y, Poiré X, Sirvent A, Kröger N, Porta F, Holter W, Bloor A, Jubert C, Ganser A, Tanase A, Ménard AL, Pioltelli P, Pérez-Simón JA, Ho A, Aljurf M, Russell N, Labussiere-Wallet H, Kerre T, Rocha V, Socié G, Risitano A, Dufour C, Peffault de Latour R; SAA WP of the EBMT.

Bone Marrow Transplant. 2019 Dec 16. doi: 10.1038/s41409-019-0773-0. [Epub ahead of print]

PMID:
31844137
9.

Romiplostim in patients undergoing hematopoietic stem cell transplantation: results of a phase 1/2 multicenter trial.

Peffault de Latour R, Chevret S, Ruggeri AL, Suarez F, Souchet L, Michonneau D, Sicre de Fontbrune F, Coman T, Dhedin N, Rubio MT, Nguyen S, Mohty M, Socié G.

Blood. 2020 Jan 16;135(3):227-229. doi: 10.1182/blood.2019000358. No abstract available.

PMID:
31805185
10.

Aplastic anemia related to thymoma: a survey on behalf of the French reference center of aplastic anemia and review of literature.

Gendron N, Sicre de Fontbrune F, Guyard A, Fadlallah J, Chantepie S, D' Aveni M, Le Calloch R, Garnier A, Couturier MA, Morel V, Bernard C, Terriou L, Lazaro E, Socié G, Peffault de Latour R.

Haematologica. 2019 Nov 14. pii: haematol.2019.226134. doi: 10.3324/haematol.2019.226134. [Epub ahead of print] No abstract available.

11.

Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial.

Beelen DW, Trenschel R, Stelljes M, Groth C, Masszi T, Reményi P, Wagner-Drouet EM, Hauptrock B, Dreger P, Luft T, Bethge W, Vogel W, Ciceri F, Peccatori J, Stölzel F, Schetelig J, Junghanß C, Grosse-Thie C, Michallet M, Labussiere-Wallet H, Schaefer-Eckart K, Dressler S, Grigoleit GU, Mielke S, Scheid C, Holtick U, Patriarca F, Medeot M, Rambaldi A, Micò MC, Niederwieser D, Franke GN, Hilgendorf I, Winkelmann NR, Russo D, Socié G, Peffault de Latour R, Holler E, Wolff D, Glass B, Casper J, Wulf G, Menzel H, Basara N, Bieniaszewska M, Stuhler G, Verbeek M, Grass S, Iori AP, Finke J, Benedetti F, Pichlmeier U, Hemmelmann C, Tribanek M, Klein A, Mylius HA, Baumgart J, Dzierzak-Mietla M, Markiewicz M.

Lancet Haematol. 2020 Jan;7(1):e28-e39. doi: 10.1016/S2352-3026(19)30157-7. Epub 2019 Oct 9.

PMID:
31606445
12.

Long-term outcome of a randomized controlled study in patients with newly diagnosed severe aplastic anemia treated with antithymocyte globuline, cyclosporine, with or without G-CSF: a Severe Aplastic Anemia Working Party Trial from the European Group of Blood and Marrow Transplantation.

Tichelli A, Peffault de Latour R, Passweg J, Knol-Bout C, Socié G, Marsh J, Schrezenmeier H, Höchsmann B, Bacigalupo A, Samarasinghe S, Rovó A, Kulasekararaj A, Röth A, Eikema DJ, Bosman P, Bader P, Risitano A, Dufour C; Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation.

Haematologica. 2019 Oct 3. pii: haematol.2019.222562. doi: 10.3324/haematol.2019.222562. [Epub ahead of print]

13.

Germline DDX41 mutations define a significant entity within adult MDS/AML patients.

Sébert M, Passet M, Raimbault A, Rahmé R, Raffoux E, Sicre de Fontbrune F, Cerrano M, Quentin S, Vasquez N, Da Costa M, Boissel N, Dombret H, Peffault de Latour R, Socié G, Itzykson R, Fenaux P, Soulier J, Adès L, Clappier E.

Blood. 2019 Oct 24;134(17):1441-1444. doi: 10.1182/blood.2019000909.

PMID:
31484648
14.

A monocentric study of steroid-refractory acute graft-versus-host disease treatment with tacrolimus and mTOR inhibitor.

Xhaard A, Launay M, Sicre de Fontbrune F, Michonneau D, Sutra Del Galy A, Coman T, Pagliuca S, Dhedin N, Robin M, Peffault de Latour R, Socie G.

Bone Marrow Transplant. 2020 Jan;55(1):86-92. doi: 10.1038/s41409-019-0633-y. Epub 2019 Aug 14.

PMID:
31413313
15.

Allogeneic reactivity-mediated endothelial cell complications after HSCT: a plea for consensual definitions.

Pagliuca S, Michonneau D, Sicre de Fontbrune F, Sutra Del Galy A, Xhaard A, Robin M, Peffault de Latour R, Socie G.

Blood Adv. 2019 Aug 13;3(15):2424-2435. doi: 10.1182/bloodadvances.2019000143. Review.

16.

Allogeneic stem cell transplantation for acquired pure red cell aplasia.

Halkes C, de Wreede LC, Knol C, Simand C, Aljurf M, Tbakhi A, Vazquez L, Bloor A, Wagner-Drouet E, Vural F, Bodova I, Isaksson C, Diaz MÁ, Gruhn B, Snowden J, Arat M, Bazarbachi A, Spilleboudt C, Kulagin A, Marsh JC, Passweg J, Risitano AM, Peffault de Latour R, Dufour C; European Society for Blood and Marrow Transplantation Severe Aplastic Anemia Working Party.

Am J Hematol. 2019 Nov;94(11):E294-E296. doi: 10.1002/ajh.25609. Epub 2019 Sep 9. No abstract available.

PMID:
31396977
17.

Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT.

Risitano AM, Marotta S, Ricci P, Marano L, Frieri C, Cacace F, Sica M, Kulasekararaj A, Calado RT, Scheinberg P, Notaro R, Peffault de Latour R.

Front Immunol. 2019 Jun 14;10:1157. doi: 10.3389/fimmu.2019.01157. eCollection 2019. Review.

18.

Efficacy and safety of brentuximab vedotin plus bendamustine in advanced-stage primary cutaneous T-cell lymphomas.

Dumont M, Ram-Wolff C, Roelens M, Brice P, Peffault de Latour R, Battistella M, Madelaine I, Delyon J, Herms F, Bouaziz JD, Moins-Teisserenc H, Lebbé C, Bagot M, de Masson A.

Br J Dermatol. 2019 Dec;181(6):1315-1317. doi: 10.1111/bjd.18215. Epub 2019 Aug 22. No abstract available.

PMID:
31206589
19.

Outcomes of Salvage Haploidentical Transplant with Post-Transplant Cyclophosphamide for Rescuing Graft Failure Patients: a Report on Behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy.

Prata PH, Resche-Rigon M, Blaise D, Socié G, Rohrlich PS, Milpied N, Turlure P, Nguyen S, Sirvent A, Bulabois CE, Berceanu A, Charbonnier A, Chevallier P, Bay JO, Neven B, Jubert C, Mohty M, Rubio MT, Peffault de Latour R.

Biol Blood Marrow Transplant. 2019 Sep;25(9):1798-1802. doi: 10.1016/j.bbmt.2019.05.013. Epub 2019 May 24.

PMID:
31129355
20.

[Graft failure after allogeneic hematopoietic stem cell transplantation: Definition and risk factors].

Alcazer V, Peffault de Latour R, Ader F, Labussière-Wallet H.

Bull Cancer. 2019 Jun;106(6):574-583. doi: 10.1016/j.bulcan.2019.03.009. Epub 2019 May 4. Review. French.

PMID:
31060736

Supplemental Content

Loading ...
Support Center